Skip to main content
. 2017 Apr 3;108(3):380–389. doi: 10.1111/cas.13153

Figure 4.

Figure 4

FKBP51 silencing decreases RhoA activation. (a) U2OS cells were transfected with Halo‐RhoA for 24 h followed by treatment with siRNA‐FKBP51 or siRNA‐control for 48 h. Cells were then subjected to the RhoA activation assay. We completed a Western blot analysis of the pulled‐down activated forms of RhoA after depletion of FKBP51. (b) The corresponding quantification of independent pull‐down experiments is shown (normalization of the GTP‐bound forms to total RhoA). Column graphs are represented as the mean ± SEM (n = 3; siRNA‐FKBP51 and siRNA‐control for the RhoA pull‐down assay). (c) Cells expressing endogenous FKBP51 or Halo‐DLC2 were visualized by anti‐FKBP51 and anti‐Halo antibodies. Glyceraldehyde 3‐phosphate dehydrogenase (GAPDH) was used as a loading control.